News

Cambridge Isotope Laboratories, Inc. (CIL) is pleased to announce the release of highly enriched ¹²C methane with low nitrogen content called ¹²C Methane QG Diamond™ for quantum applications in the field of color and nitrogen vacancy CVD diamonds. ¹²C Methane QG Diamond will be useful for academics focused on quantum research, those developing diamonds with specific color properties or nitrogen-vacancy (NV) centers, and producers of industrial diamonds. The process of such applications begins with ¹²C-enriched methane.

New Location Positions CIL for Product Development and Future Growth 
Cambridge Isotope Laboratories, Inc. (CIL), the world leader in stable isotope chemistry and the separation of carbon-13 (¹³C), has announced it will be relocating and expanding its corporate headquarters to newly purchased space in Tewksbury, MA, to advance the operations and growth of the company. The purchase was made in June 2023. 

Cambridge Isotope Laboratories, Inc. (CIL), the world leader in stable isotope chemistry and the separation of carbon-13 (¹³C), has embarked on the largest expansion in the company’s history. This strategic undertaking, which has been aptly named North Star, will significantly increase ¹³C production by building a separate cryogenic distillation facility for carbon monoxide.

Cambridge Isotope Laboratories, Inc. (CIL) has partnered with ISOtopic Solutions to release the new stable isotope-labeled and unlabeled Crude Lipid Yeast Extracts. These are designed to render 100s of fatty acids and lipids for use in MS lipidomics research and development.

Cambridge Isotope Laboratories, Inc., the world’s leading manufacturer of stable isotopes and stable isotope-labeled compounds, is pleased to announce the addition of John Bakke as Vice President of Finance. John reports directly to the CEO, Cliff Caldwell.

Otsuka Pharmaceutical Co., Ltd (Otsuka) is pleased to announce that ABX advanced biochemical compounds GmbH (ABX), a subsidiary of Cambridge Isotope Laboratories, Inc. (CIL), which in turn is a wholly owned subsidiary of Otsuka, expects to receive payments and royalties from Endocyte Inc., a Novartis company, based on the US FDA regulatory approval of Pluvicto™ (lutetium Lu 177 vipivotide tetraxetan), formerly referred to as 177Lu-PSMA-617, a radioligand therapy for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor pathway inhibition and taxane-based chemotherapy.

Cambridge Isotope Laboratories, Inc. (CIL) is pleased to announce the hire of Ashley Schultz as a new Regional Sales Manager. Schultz will lead sales for CIL in the Mid-Atlantic and Southeast regions, covering Pennsylvania, Delaware, Maryland, West Virginia, Virginia, Kentucky, Tennessee, North Carolina, South Carolina, Alabama, Georgia, and Florida.

Cambridge Isotope Laboratories, Inc. (CIL) is pleased to announce the release of its new stable isotope-labeled and unlabeled TCA cycle mixes to aid in the analysis of TCA-associated compounds in metabolic studies. The TCA (tricarboxylic acid) cycle, also known as the Krebs or citric acid cycle, plays an essential role in central carbon and energy metabolism. The study of its intermediates, and its ancillary compounds, has proven pivotal in not only understanding their impact on metabolism but also in profiling their function in oncogenesis, inflammation, and other pathologies.

Cambridge Isotope Laboratories, Inc. (CIL) now offers solutions for testing the quality and safety of cannabis products with the launch of a variety of stable isotope-labeled and native standards of THC, CBD, and other cannabinoids to assist with testing needs.

Cambridge Isotope Laboratories, Inc. (CIL), part of the Otsuka Group and the world's leading producer of stable isotopes and stable isotope-labeled compounds, is proud to launch the first commercially available ¹²C-enriched methane-grade gas for quantum applications.

Cambridge Isotope Laboratories, Inc. is entering a global, strategic partnership with Bruker BioSpin for the distribution of CIL’s NMR solvents.

Cambridge Isotope Laboratories, Inc. (CIL),  the world leader in stable isotope chemistry and the separation of carbon-13 (¹³C), recently began a significant capacity optimization of one of the production cascades at the ¹³C separation facility in Xenia, OH. This optimization, which began this past summer and is scheduled for completion in the summer of 2021, will increase the cascade’s ¹³C production by 10%. This follows the most recent expansion completion earlier this year, which increased ¹³C production capacity by 25%.

Eurisotop, a wholly owned subsidiary of Cambridge Isotope Laboratories, Inc. (CIL), announced a capacity expansion of its deuterated chloroform production. Since its acquisition by CIL in 2001, Eurisotop has become a leading producer of deuterated NMR solvents and is the premier supplier of CIL stable isotope-labeled compounds in Europe.

Cambridge Isotope Laboratories, Inc. (CIL), the world leader in stable isotopes and stable isotope-labeled compounds, recently announced a capacity expansion for deuterated benzene at CIL Isotope Separations, LLC (CIS), located on 33 acres in Xenia, OH.

Cambridge Isotope Laboratories, Inc. (CIL), the world leader in stable isotope chemistry and the separation of carbon-13 (¹³C), recently completed a significant expansion of its ¹³C separation facility.

Cambridge Isotope Laboratories, Inc., the leading manufacturer of stable isotope and stable isotope-labeled compounds worldwide, is pleased to announce the addition of Todd Osiek, PhD, as Chief Science Officer (CSO).

Cambridge Isotope Laboratories, Inc, the world’s leading manufacturer of stable isotopes and stable isotope-labeled compounds, is pleased to announce the addition of Warren Arenz as Vice President of Operations. Arenz reports directly to the CEO, Cliff Caldwell.

CIL recognizes the high level of food insecurities due to COVID-19 and wanted to give to the surrounding communities in need. To help those facing food insecurity in the wake of the COVID-19 outbreak, CIL held a food and personal care item drive supporting the Lawrence YMCA Food Pantry, partner of the Merrimack Valley Food Bank, Inc.

Cambridge Isotope Labs (CIL) is proud to offer an assortment of deuterated phospholipids and detergents manufactured by FB Reagents, Ltd. These compounds are being used to solubilize isotopically labeled membrane proteins for high-field nuclear magnetic resonance (NMR) spectroscopy, and to study membrane structure by small-angle neutron scattering (SANS). FBR’s products expand significantly CIL’s current offering of deuterated lipids and detergents.

CIL is aiding COVID-19-related research currently being conducted in the laboratory of Dr. Mei Hong, a professor of chemistry at MIT (Cambridge, MA.). The Hong laboratory develops and applies magic-angle-spinning solid-state NMR spectroscopy to elucidate the structure and dynamics of biological macromolecules. One current research focus of the Hong group is to determine the structure and binding mechanism of a severe acute respiratory syndrome coronavirus 2 (SARS CoV 2) membrane protein.

Through a commercial partnership with Alsachim, Cambridge Isotope Laboratories, Inc. (CIL) is proud to now offer an assortment of unlabeled and stable isotope-labeled antiviral drug standards and their metabolites to assist in COVID-19 research and therapy development.

As we continue to monitor and respond to the changing business dynamics created by the coronavirus (COVID-19), the entire CIL team extends our best wishes to you, your employees, and families for good health and peace of mind during a difficult time.

Cambridge Isotope Laboratories, Inc. (CIL) Board of Directors appointed Cliff Caldwell as its new chief executive officer (CEO), as Joel Bradley, founder and CEO, stepped down from his position after 38 years. Bradley will remain as a member of the board of directors and will continue to consult for the company.

Cambridge Isotope Laboratories, Inc. (CIL), an indirect subsidiary of Otsuka Holdings Co., Ltd., announces that the latter has signed the CEO Statement of Support for the Women’s Empowerment Principles (WEPs), a set of principles focusing on corporate action to promote gender equality and women’s empowerment in the workplace, marketplace and community.

Endocyte, Inc. (NASDAQ Global Market: ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced the completion of an exclusive worldwide license of PSMA-617 from ABX GmbH.

Cambridge Isotope Laboratories, Inc. is pleased that the Food and Drug Administration (FDA) approved the first deuterated drug, AUSTEDO™ by Teva (previously referred to as SD-809).

Cambridge Isotope Laboratories, Inc. (CIL), the world’s leading supplier of stable isotopes and stable isotope-enriched compounds, is pleased to offer Mouse Express^® NeuCode™ mouse feed with different combinations of lysine (Lys) isotopologues for 2- and 3-plex, MS proteomic analysis.

Cambridge Isotope Laboratories, Inc. (CIL), the world’s leading supplier of stable isotopes and stable isotope-labeled compounds, is working together with IROA Technologies LLC (IROATECH), a leading developer of novel analytical tools for accurate metabolic analysis, to help develop and distribute IROA^® Biochemical Quantitation Kits worldwide for metabolic profiling of various cell populations and biological samples.

POPs research is growing rapidly in China, and use of isotope dilution mass spectrometry (IDMS) has been shown to be the most robust method for accurate and precise POPs analysis. Cambridge Isotope Laboratories, Inc. (CIL) has partnered with RCEES, Tongji University, and Zhejiang University to hold three symposia for Chinese POPs research using IDMS.

Cambridge Isotope Laboratories, Inc. (CIL), the world’s leading supplier of stable isotopes and stable isotope-enriched small molecules, is working together with Nexomics Biosciences, a structural biology and protein production contract research organization, to provide isotope-labeled proteins to life science research organizations.

CIL, the world’s leader in the manufacturing of stable isotope-labeled research chemicals, has entered into a distributor agreement with CellFree Sciences Co., Ltd. for the distribution of CFS’s WEPRO^® Expression Kits and reagents for cell-free protein production for NMR and mass spectrometry applications in North America and Europe. CIL will provide stable isotope-enriched amino acids as a component in the WEPRO Expression Kits.